ArticleClinical and translational radiation oncology2024

Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer.

Ingrid Masson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.